Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus

Jason Swindle, Xin Ye, Rajiv Mallick, Rui Song, Thomas Horstman, Harold BaysAnnals 2014 · DOI

Abstract

In this health care database analysis among patients with HCh and T2DM, colesevelam was associated with decreased risk of a composite CV event compared with ezetimibe, despite lower persistence.
BibTeX
@article{swindle2014colesevelam,
  author = {Jason Swindle and Xin Ye and Rajiv Mallick and Rui Song and Thomas Horstman and Harold Bays},
  title = {{Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus}},
  journal = {Annals},
  year = {2014},
  doi = {10.1177/1060028014531737},
}

Loading related content...

Figure